Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia

Lewis, Bruce E.; Wallis, Diane E.; Berkowitz, Scott D.; Matthai, William H.; Fareed, Jawed; Walenga, Jeanine M.; Bartholomew, John R.; Sham, Ronald L.; Lerner, Robert G.; Zeigler, Zella R.; Rustagi, Pradip K.; Jang, Ik‐Kyung; Rifkin, S. D.; Moran, John F.; Hursting, Marcie J.; Kelton, John G.

doi:10.1161/01.cir.103.14.1838

Cited by 626 publications

(668 citation statements)

References 23 publications

Supporting

Mentioning

643

Contrasting

Unclassified

Order By: Relevance

“…It is not fully appreciated that patients with HIT are at high risk for new or recurrent thromboses during a period of 30-60 days after the diagnosis is made [58,68,69]. Accordingly, anticoagulation should be maintained during that time frame.…”

Section: Treatmentmentioning

confidence: 99%

Heparin‐induced thrombocytopenia and thrombosis

Davoren

Aster

2005

American J Hematol

View full text Add to dashboard Cite

Heparin, employed clinically for more than 50 years, is still a widely used anticoagulant. Unfortunately, some patients given this agent develop thrombocytopenia and thrombosis. Because this side effect can have catastrophic consequences, it is imperative that all clinicians caring for patients who receive heparin have at least a basic understanding of its pathogenesis, diagnosis, and management. Am. J. Hematol. 81:36-44, 2006Hematol. 81:36-44, . ª 2005 Wiley-Liss, Inc.

show abstract

Section: Treatmentmentioning

confidence: 99%

Heparin‐induced thrombocytopenia and thrombosis

Davoren

Aster

2005

American J Hematol

View full text Add to dashboard Cite

show abstract

“…Arterial thrombosis occurs more commonly in the lower limbs, followed by cerebral arteries and lastly the coronary arteries, the reversal order of atherothrombosis. Several retrospective cohort studies [115][116][117][118] indicate that among patients who develop isolated HIT, 25-50% will develop clinically evident thrombosis after stopping heparin, with or without substitution by coumadin, usually within the first week [119,120]. The risk of fatal thrombosis is 5% [115].…”

Section: Clinical Presentationmentioning

confidence: 99%

Thrombocytopenic conditions—autoimmunity and hypercoagulability: Commonalities and differences in ITP, TTP, HIT, and APS

Kravitz

Shoenfeld

2005

American J Hematol

View full text Add to dashboard Cite

Immune thrombocytopenia purpura (ITP), thrombotic thrombocytopenia purpura (TTP), heparin‐induced thrombocytopenia (HIT), and antiphospholipid syndrome (APS) are clinical conditions associated with significant morbidity and mortality. These well‐defined clinical syndromes have in common several properties: (1) their pathogenesis is immune mediated, specifically by autoantibodies; (2) thrombocytopenia is a hallmark in these four conditions; (3) except for the case of ITP, platelet and endothelial cell activation occurs in TTP, HIT, and APS, resulting in a prothrombotic state and an increased risk of thrombosis. Although these four immune‐mediated syndromes are well‐defined diseases, several case reports and studies have documented the association of two diseases in the same patient, illustrating the concept of the kaleidoscope of autoimmunity. Am. J. Hematol. 80:232–242, 2005. © 2005 Wiley‐Liss, Inc.

show abstract

“…Heparin's contraindication in patients with acute HIT necessitates the use of alternative agents when these patients require anticoagulation in association with cardiovascular surgery. Appropriate agents are either a direct thrombin inhibitor (DTI) such as lepirudin, argatroban, and bivalirudin, or the heparinoid factor Xa inhibitor, danaparoid [10,11].…”

Section: Discussionmentioning

confidence: 99%

Coronary arterial bypass surgery with beating heart in a patient with heparin-induced thrombocytopenia: Usage of thrombin inhibitor (Lepirudin; r-hirudin)

et al. 2010

View full text Add to dashboard Cite

AbstractOne of the most important adverse drug reactions that physicians encounter is the life-threatening prothrombotic syndrome known as heparin-induced thrombocytopenia (HIT). In patients with a history of heparin-induced thrombocytopenia and coronary arterial disease, alternative anticoagulatory regimens are needed during cardiac surgery for prevention of thrombosis. Treatment options for such patients now generally include the use of alternative anticoagulants such as lepirudin, bivalirudin, argatroban or danaparoid. In this article, we present a case where heparin-induced thrombocytopenia was properly performed coronary arterial bypass grafting by using lepirudin. (This sentence is confusing)

show abstract

Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia

Abstract: Argatroban anticoagulation, compared with historical control subjects, improves clinical outcomes in patients who have heparin-induced thrombocytopenia, without increasing bleeding risk.

Cited by 626 publications

References 23 publications

Heparin‐induced thrombocytopenia and thrombosis

Heparin‐induced thrombocytopenia and thrombosis

Thrombocytopenic conditions—autoimmunity and hypercoagulability: Commonalities and differences in ITP, TTP, HIT, and APS

Coronary arterial bypass surgery with beating heart in a patient with heparin-induced thrombocytopenia: Usage of thrombin inhibitor (Lepirudin; r-hirudin)

Contact Info

Product

Resources

About